KLRK1 and B-cell chronic lymphocytic leukemia: Similar to our cytotoxic assays with the (ULBP2-aCD19-aCD33) TBs in response to leukemia cell lines and primary AML blasts, designed NKG2D-stimulating TBs that contained targeting against CD19 antigens (ULBP2-aCD19-aCD19) only displayed strong affinity to CD19 surface molecules on CLL cells.